Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 20,720.0 | 19,820.0 | 17,224.0 | 16,652.0 | 14,950.0 | 14,024.0 | 13,211.0 | 12,893.0 |
| Revenue growth | 4.5% | 15.1% | 3.4% | 11.4% | 6.6% | 6.2% | 2.5% | -0.4% |
| Cost of goods sold | 28,511.0 | 15,508.0 | 14,158.0 | 13,975.0 | 12,189.0 | 11,369.0 | 10,780.0 | 10,474.0 |
| Gross profit | -7,791.0 | 4,312.0 | 3,066.0 | 2,677.0 | 2,761.0 | 2,655.0 | 2,431.0 | 2,419.0 |
| Gross margin | -37.6% | 21.8% | 17.8% | 16.1% | 18.5% | 18.9% | 18.4% | 18.8% |
| Selling, general and administrative | 4,369.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITA | 4,280.0 | 4,758.0 | 3,428.0 | 2,991.0 | 2,944.0 | 2,824.0 | 2,570.0 | 2,573.0 |
| EBITA margin | 20.7% | 24.0% | 19.9% | 18.0% | 19.7% | 20.1% | 19.5% | 20.0% |
| Amortization of intangibles | | 365.0 | 351.0 | 314.0 | 183.0 | 169.0 | 130.0 | 109.0 |
| EBIT | 4,280.0 | 4,393.0 | 3,077.0 | 2,677.0 | 2,761.0 | 2,655.0 | 2,440.0 | 2,464.0 |
| EBIT margin | 20.7% | 22.2% | 17.9% | 16.1% | 18.5% | 18.9% | 18.5% | 19.1% |
| Pre-tax income | 4,082.0 | 4,208.0 | 2,793.0 | 2,439.0 | 2,244.0 | 2,643.0 | 2,480.0 | 2,307.0 |
| Income taxes | 995.0 | 1,034.0 | 747.0 | 666.0 | 574.0 | 1,133.0 | 685.0 | 671.0 |
| Tax rate | 24.4% | 24.6% | 26.7% | 27.3% | 25.6% | 42.9% | 27.6% | 29.1% |
| Earnings from continuing ops | 3,050.0 | 3,143.0 | 2,016.0 | 1,742.0 | 1,650.0 | 1,490.0 | 1,768.0 | 1,599.0 |
| Earnings from discontinued ops | | | | | | 2.0 | | |
| Net income | 3,050.0 | 3,143.0 | 2,016.0 | 1,742.0 | 1,650.0 | 1,492.0 | 1,768.0 | 1,599.0 |
| Net margin | 14.7% | 15.9% | 11.7% | 10.5% | 11.0% | 10.6% | 13.4% | 12.4% |
| |
| Diluted EPS | $6.04 | $6.13 | $3.94 | $3.41 | $3.23 | $2.87 | $3.37 | $2.98 |
| Shares outstanding (diluted) | 505.0 | 513.0 | 512.0 | 511.0 | 511.0 | 519.0 | 524.0 | 536.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|